GlobeNewswire

NRT Technology Completes Acquisition of VisuaLimits, One of the Fastest Growing Gaming Supplier Companies in the US

Dela

Acquisition of VisuaLimits Strengthens NRT's Ability to Connect the Guest Experience(TM) Across the Entire Casino Resort

LAS VEGAS, Sept. 26, 2017 (GLOBE NEWSWIRE) -- NRT Technologies, Inc.,  a wholly-owned subsidiary of NRT Technology Corp. (together, "NRT") today announced the successful completion of its acquisition of VisuaLimits, LLC ("VL").   On September 20 2017, NRT and Sightline Payments announced an agreement to merge, with the combined entity to be called NRT Sightline (the "Transaction").  Following close of the Transaction, which remains subject to gaming regulatory approvals, Sightline's CEO and Founder, Kirk Sanford, will assume the role of CEO of NRT Sightline. NRT's current Founder, President and CEO, John Dominelli, will become Chairman of NRT Sightline and will remain active in leading the overall company strategy with a keen focus on driving the technology roadmap.

The acquisition of VL complements NRT's innovative and expansive payment product vision for casinos, which now includes VL's unique 12-in-1 solution.

The VL-Focus and VL-Flex, with their highly adaptive hardware and software, delivers a multitude of services to casino operators and patrons alike, including cashless payments through integration with Sightline's Play+, an HD display for gaming, TV, sports score and advertising messaging, dealer performance (automated hands per hour) and game utilization (automated headcounts), labor savings with time and attendance through Kronos integration, sophisticated surveillance, and 2-way communication functionality which allows dealers to easily contact security, place food and drink orders, and make dinner or club reservation for players.  And because casino operators can easily integrate VL platforms into their existing table rating system, VL offers the added benefit of eliminating the clutter and extra price of redundant hardware. Casino operators can often realize their ROI on VL-Focus and VL-Flex purchases in less than 3 months.

VL's newest product, the VL-EYE, interfaces with the VL-Focus to provide a full surveillance system, including facial, chip, and card recognition capabilities.  Casinos are lining up to be beta sites prior to the VL-EYE's launch next month at G2E. 

"Just in the last year alone VL has tripled its installed base and will finish this year with over 4000 'intelligent' VL-Focus devices, adding some well recognized names to its roster of casino customers, including 8 of the top 10 Global casino operators," said Dominelli.  "And we couldn't be happier with the people that will be joining NRT as part of this acquisition.  They bring a real passion and unparalleled expertise to our organization that will truly enable NRT to Connect the Guest Experience across the entire casino resort."

"The VL platform is like nothing else out there. We deliver actionable insights to operators, delivering tangible business improvements, transactional lift from payments, automated workflows, operational performance improvements and dynamic regulatory compliance. And operators love VL because our solutions consolidate the typical array of table games hardware to de-clutter and improve the overall 'look and feel' of gaming tables," said Ryan McClellan, VL's Co-Founder and former COO who now takes on the role of  SVP Table Game Solutions for NRT.   

"We have received such overwhelmingly positive feedback from operators about the VL product and this, coupled with the excitement of the recently announced VL integration with Sightline's Play+ solution, convinced us that acquiring VL made more sense than continuing under a partnership arrangement," said Michael Dominelli, VP Product and Marketing for NRT.  "Ryan McClellan and his team have built a truly amazing product suite.  The VL platform, along with our slot machine and redemption kiosk integrations, and pending merger with Sightline, will allow the combined entity to provide a frictionless payment experience throughout the entire casino ecosystem."

Financing for the VL acquisition was provided by Fifth Third Bank

About NRT & Sightline

On closing, NRT Sightline(TM) is a global leader in the design and development of enterprise platforms for the casino industry. Every year we enable more than 1 billion physical and digital commerce experiences at over 600 casino properties worldwide.  By seamlessly combining technological innovation with strategic partnerships, we create the most convenient, reliable, and secure omni-channel payment ecosystem for casino operators and their guests. NRT Sightline has been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for our Play+(TM) cloud-based cashless funding platform. Our solutions are used by casinos, lotteries, race and sports, banking & retailers around the world. We operate across 7 countries and have corporate offices in Las Vegas, Toronto, Macau, and Singapore.

For further information about Sightline or its pending merger with NRT, please contact Omer Sattar, Sightline's EVP Strategic Relationships osattar@sightlinepayments.com.

Sightline's Play+ is patent protected by United States Patent Nos. 8,708,809, 8,777,725, 8,998,708, 9,196,123, 9,245,413, 9,251,651, 9,466,176, 9,

715,785, 9, 715,787 and 9,721,430.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum